Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
LILLY (ELI) & COMPANY - Additional Phase III Clinical Trials LILLY (ELI) & COMPANY - Additional Phase III Clinical Trials PR...
LILLY (ELI) & COMPANY - 2012 Financial Guidance;2013 Financial Guidance LILLY (ELI) & COMPANY - 2012 Financial Guidance;2013 Financial...
LILLY (ELI) & COMPANY - SEC Settlement Press Release LILLY (ELI) & COMPANY - SEC Settlement Press Release PR Newswire London, December...
LILLY (ELI) & COMPANY - LLY Sets Dates for Financial Guidance & Q4 2012 Results LILLY (ELI) & COMPANY - LLY Sets Dates for...
LILLY (ELI) & COMPANY - Tabalumab RA Study BCDM Discontinuation LILLY (ELI) & COMPANY - Tabalumab RA Study BCDM Discontinuation PR...
LILLY (ELI) & COMPANY - Next Steps for Solanezumab LILLY (ELI) & COMPANY - Next Steps for Solanezumab PR Newswire London, December 12...
LILLY (ELI) & COMPANY - Cardiovascular outcome study on Tradjenta® (linagliptin) LILLY (ELI) & COMPANY - Cardiovascular outcome study...
LILLY (ELI) & COMPANY - EC approves Cialis - benign prostatic hyperplasia LILLY (ELI) & COMPANY - EC approves Cialis - benign prostatic...
LILLY (ELI) & COMPANY - 3rd Quarter Results LILLY (ELI) & COMPANY - 3rd Quarter Results PR Newswire London, October 25 Eli Lilly and...
LILLY (ELI) & COMPANY - Dula Topline Release LILLY (ELI) & COMPANY - Dula Topline Release PR Newswire London, October 22 Date: October...
LILLY (ELI) & COMPANY - Amyvid Recommended for Approval in EU LILLY (ELI) & COMPANY - Amyvid Recommended for Approval in EU PR...
LILLY (ELI) & COMPANY - FDA Approves New Use of ALIMTA LILLY (ELI) & COMPANY - FDA Approves New Use of ALIMTA PR Newswire London...
LILLY (ELI) & COMPANY - Lilly Declares Q4 2012 Dividend LILLY (ELI) & COMPANY - Lilly Declares Q4 2012 Dividend PR Newswire London...
LILLY (ELI) & COMPANY - Mechanistic Differences Between FORTEO & Zoledronic Acid LILLY (ELI) & COMPANY - Mechanistic Differences...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지